• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2012 Product Image

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2012

  • ID: 2366408
  • December 2012
  • 113 pages
  • Global Markets Direct

Anaplastic Large Cell Lymphoma (ALCL) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL). Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Anaplastic Large Cell Lymphoma READ MORE >

2
List of Tables 6
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Anaplastic Large Cell Lymphoma (ALCL) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) 9
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics under Development by Companies 11
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics – Products under Development by Companies 18
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Development 20
Seattle Genetics, Inc. 20
Eisai Co., Ltd. 21
Teva Pharmaceutical Industries Limited 22
Sareum Holdings plc 23
Nerviano Medical Sciences S.r.l. 24
Xencor, Inc. 25
Anaplastic Large Cell Lymphoma (ALCL) – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 33
CEP-28122 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
brentuximab vedotin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
brentuximab vedotin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
denileukin diftitox - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
XmAb-2513 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Campath + Fludarabine + Cyclosporine + Mycophenolate Mofetil + Peripheral Stem Cell Transplantation - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 44
RAD001 + Revlimid - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
RAD001 + CHOP - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 47
Busulfan + Cyclophosphamide + Allogeneic Bone Marrow Transplantation + Methylprednisolone + Methotrexate + Cyclosporine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 49
Lenalidomide + Rituximab + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplant - Drug Profile 50
Product Description 50
Mechanism of Action 51
R&D Progress 51
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile 53
Product Description 53
Mechanism of Action 54
R&D Progress 55
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Cyclosporine + Mycophenolate Mofetil + Melphalan + Therapeutic Autologous Lymphocytes + Stem Cell Transplantation + Radiation Therapy - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 57
Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Leucovorin Calcium + Methotrexate + Therapeutic Hydrocortisone + Vinblastine - Drug Profile 59
Product Description 59
Mechanism of Action 60
R&D Progress 61
Fludarabine Phosphate + Total-Body Irradiation + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 64
Vidaza + Velcade - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
crizotinib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CEP-37440 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
SGN-35 + Cyclophosphamide + Prednisone + Doxorubicin + Vincristine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 69
Aurora + ALK Program - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
carfilzomib - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SGN-35 + Cyclophosphamide + Prednisone + Doxorubicin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 73
131I-BC8 (Anti-CD45) Antibody + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
NMS-E628 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics – Drug Profile Updates 76
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics – Discontinued Products 97
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics - Dormant Products 98
Anaplastic Large Cell Lymphoma (ALCL) – Product Development Milestones 99
Featured News & Press Releases 99
Nov 05, 2012: Seattle Genetics To Present Data On Adcetris And Antibody-Drug Conjugates At American Society Of Hematology Annual Meeting 99
Oct 31, 2012: Takeda And Millennium Announce European Conditional Marketing Authorization For Adcetris 100
Oct 01, 2012: Millennium And Seattle Genetics Highlight Data From ADCETRIS Trial In Patients With Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma 101
Jul 20, 2012: Millennium And Takeda Announce Positive CHMP Opinion For Conditional Approval Of ADCETRIS In Europe 103
Jun 02, 2012: Seattle Genetics To Present Adcetris Clinical Data In Multiple Presentations At ASCO Annual Meeting 104
May 23, 2012: Phase II Trial Results Of Brentuximab Vedotin Published In Journal Of Clinical Oncology 106
May 23, 2012: Seattle Genetics's ADCETRIS New Drug Submission Accepted For Review By Health Canada 107
May 16, 2012: Children's Oncology Group Phase I Trial Of Crizotinib Achieves Positive Response 108
May 16, 2012: Crizotinib Shows Benefit In Children With Previously Treated Cancers In NIH-Supported Trial 109
Mar 26, 2012: Seattle Genetics Announces Pivotal ADCETRIS Hodgkin Lymphoma Study Published in Journal of Clinical Oncology 110
Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 113
Disclaimer 113

List of Tables
Number of Products Under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2012 9
Products under Development for Anaplastic Large Cell Lymphoma (ALCL) – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Seattle Genetics, Inc., H2 2012 20
Eisai Co., Ltd., H2 2012 21
Teva Pharmaceutical Industries Limited, H2 2012 22
Sareum Holdings plc, H2 2012 23
Nerviano Medical Sciences S.r.l., H2 2012 24
Xencor, Inc., H2 2012 25
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 32
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics – Drug Profile Updates 76
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics – Discontinued Products 97
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics – Dormant Products 98

List of Figures
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2012 9
Products under Development for Anaplastic Large Cell Lymphoma (ALCL) – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos